News

News Subscription

Mar 11. 2024
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Feb 13. 2024 / Ad hoc announcement
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Read more
Download
Jan 19. 2024
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
Read more
Download
Jan 15. 2024
Basilea announces acquisition of preclinical antibiotics program from Spexis
Read more
Download
Jan 05. 2024
Basilea provides portfolio status update
Read more
Download
Dec 20. 2023 / Ad hoc announcement
Basilea announces accelerated loan repayment
Read more
Download
Dec 11. 2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
Read more
Download
Nov 20. 2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
Read more
Download
Nov 13. 2023 / Ad hoc announcement
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
Read more
Download
Oct 31. 2023 / Ad hoc announcement
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
Read more
Download